MOLECULAR IMAGING AND PEPTIDE RECEPTOR MOLECULAR

Loading...

MOLECULAR IMAGING AND PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRNT) OF NEUROENDOCRINE TUMORS: CURRENT STATE AND FUTURE PERSPECTIVES Professor Dr. Richard P. Baum Department of Nuclear Medicine , Center for PET/CT Zentralklinik Bad Berka, Germany [email protected] [DOTA0-d-Phe1-1-Nal3]-octreotide

DOTA-NOC

DOTA-OC

DOTA-TOC

A Annual lM Meeting ti off the th Czech C h Cooperative C ti Group G for f NETs NET (KSPNN) PRUHONICE, April 29, 2011

Summary 68Ge/Ga Generator ¾ Post-processing of 68Ge/68Ga radionuclide generators using cation exchange resin provides chemically and radiochemically pure 68Ga (97±2%) within 4 min ready for on-line labelling

¾ Highest chemical purity guarantees for high labeling and overall product yields (e.g. 68Ga-DOTA-conjugated octreotides) of 75±5% decay corrected ¾ Ready for injection – up to 10 patients per day can be studied easy handling in a nuclear medical environment easilyy to transfer to IAEA and other countries Significant step towards the routine medical use of the 68Ge/Ga generator

68Ga-DOTA-TOC

versus 111In In-DOTA-TOC DOTA TOC and 99mTc Tc-HYNIC-TOC HYNIC TOC Gabriel et al. J Nucl Med 2007; 48: 508-518

PET

SPECT

CT

Results (n=84 Patients - NET) Sensiti vity

97% (69/71)

52% (37/71)

61% (41/67)

Specifi p city

92% ((12/13))

92% ((12/13))

71% ((12/17))

Accu racy

96% ((81/84))

58% ((49/84))

63% ((53/84))

C bi d Use Combined U off PET and d CT provides id the th highest hi h t accuracy Das Bild k ann nicht angezeigt werden. Dieser Computer v erfügt möglicherweise über zu wenig A rbeitsspeicher, um das Bild zu öffnen, oder das Bild ist beschädigt. Starten Sie den Computer neu, und öffnen Sie dann erneut die Datei. Wenn weiterhin das rote x angezeigt wird, müssen Sie das Bild möglicherweise löschen und dann erneut einfügen.

Univ.-Klinik für Nuklearmedizin

Affinity profiles (IC50) for human sst 2–5 receptors C Compound d

h 2 hsst2

h 3 hsst3

h 4 hsst4

h 5 hsst5

SS-28

2.5±0.3

5.7±0.6

4.2±0.3

3.7±0.4

IInIII-DOTA-NOC DOTA NOC

2 9±0 1 2.9±0.1

8±2

227±18

11 2±3 5 11.2±3.5

YIII-DOTA-NOC

3.3±0.2

26±1.9

>1,000

10.4±1.6

YIII-DOTA-TOC DOTA TOC

11 4±1 7 11.4±1.7

389±136

>10 000 >10,000

204±92

YIII-DOTA-OC

20±2.2

27±8

>1000

58±22

YIII-DOTA-LAN DOTA LAN

22 8±4 9 22.8±4.9

290±105

>1000

16 3±3 4 16.3±3.4

Wild D, Schmitt SJ, Ginj M, Mäcke HR, Bernard BF, Krenning E, de Jong M, Wenger S and Reubi J-C. Eur J Nucl Med Mol Imaging 2003;30:1338

*

* Awarded the best scientific research paper in the EJNMMI in 2003 [DOTA0-d-Phe1-1-Nal3]-octreotide

DOTA-NOC

DOTA-OC

DOTA-TOC

In Wahl R. (ed.): ( ) Principles and Practice of PET and PET/CT. Lippincott Williams & Wilkins, Philadelphia 2008 (p. 411-437).

Principles and Clinical Indications

Neuroendocrine Tumors (NET) – Diagnosis – Suspicion of NET Diagnostic Methods:

Typical T i l Symptoms S t ⇒ Diagnostic Pathways

Tests for Hormone Production

• (Endo-) Sonograpy • Endoscopy • MRI (CT S Scan)) • Somatostatin Receptor p PET/CT or Scintigraphy (SRS)

Imaging Procedures Th Therapy

Foregut

Midgut

Hindgut

Ga-68 SMS Receptor PET – Imaging Technique Images courtesy Heiner Bihl/Gabriele Pöpperl Klinik für Nuklearmedizin •Katharinen-Hospital, •Katharinen Hospital Stuttgart

0:20 p p.i. i

0:40 p p.i. i

1:00 p p.i. i

1:20 p p.i. i

1:40 p p.i. i

Injected activity: 1.5 MBq/kg (100-150 MBq, 3-4 mCi). 20 mg Lasix iv Start of acquisition: 60-90 min p.i. (30-180 min) Acquisition parameters: 2 min. per bed position Effective radiation dose: 3 mSv for 150 MBq 68Ga-DOTATOC (+CT) (Octreoscan® 12 mSv) Imaging characteristics: fast kinetics, fast renal clearance, high quality images with very low background high tumor uptake allows detection of very small lesions (3 to 5 mm) already 30 to 60 min. p.i. Image analysis: visual and quantitative (SUV) evaluation

Staging g g of NET by y Receptor-PET/CT ¾ Whole-body Whole body diagnosis („one-stop ( one stop shop“) shop ) ¾ Detection of unknown pprimaryy tumors (CUP) ( ) ¾ Evaluation of receptor status before PRRT or octreotide therapy

Indication

Re staging Follow-up Re-staging, Follow up e.g. in patients with rising tumor markers ((chromogranin, g , serotonin,, calcitonin,, glucagon) g g ) for detection of recurrence

Indication Patient evaluation before PRRT Receptor density – determined by receptor PET/CT: semiquantitative measurement by

SUV (Standardized Uptake Values)

Biodistribution Bi di t ib ti off th the G Ga-68 68 labeled l b l d somatostatin analog g DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. V. Prasad, V Prasad R.P. R P Baum Q J Nucl Med Mol Imaging 2010; 54:61-67

Ga-68 DOTA-NOC receptor PET/CT: SUV of primary tumors and metastases SUV in primary tumors and metastases (n = 1 1,400 400 studies)

Mean

Range

Primary tumors

19.2

8.2 – 109

Liver mets

20.9

3.3 - 105

Lymph node mets

9.5

4.2 – 152

Bone mets

13.6

3.0 – 20.4

Brain mets

12.3

4.6 – 17.2

Lung mets

2.3

1.6 – 5.6

Abdominal mets

14.8

5.8 – 34.1

Somatostatin receptor imaging using Ga-68 DOTA-NOC PET/CT gives accurate estimation of the receptor density density.

IRS Score for SSTR2A proportional to SUVmax and SUVmean

IRS Score for SSTR5 proportional to SUVmax

p<0.05

SSTR1 SSTR3

SSTR4

No significant correlation between the IRS score for SSTR1, SSTR3 and SSTR4 with the semiquantitative parameters p>0.05

Evaluation of therapy py response p Problems of using WHO or RECIST criteria: it i ¾

1 or 2-dimensions 2 dimensions only

¾

what is the amount of vital tumor?

Morphologic Response Criteria R Response CR

WHO Cancer 1981;47 207-14

complete disappearance of all disease manifestations in two observations at an interval of at least 4 weeks

PR

SD

PD

≥ 50 % decrease in tumor size

↑ or ↓ in tumor size of < 25 %

> 25 % increase in tumor lesions and/or appearance of new foci of tumor

Neither WHO nor RECIST criteria address tumor response with biological atand metabolic markers. least 30% RECIST J N CI 2000;92 ; 205–16

disappearance of all tumor lesions

decrease in the sum of longest diameter of tumor lesion

neither PR nor PD

at least 20 % increase in sum of the longest diameter of tumor lesion

Monitoring Response to Therapy

DESIST USE

RECIST

PERCIST

MOLECULAR RESPONSE PRECEDES MORPHOLOGY !

PET/CT in NET: Diagnostic Algorithm - Staging/CUP Functional Activity

Proliferation Index (Ki-67)

<20 %

>20 %

Ga-68-SMS (DOTA-TOC / DOTA-TATE / DOTA-NOC)

Negative

Present

F-18-FDG

F-18-DOPA F-18 DOPAMINE

Absent CgA / SYN +

In all patients, once (initially) Negative Positive Positive Negative FDG-PET/CT should be done

Positive

MDT / CDM* W+S OP PRRT TACE / SIRT Chemo

CgA / SYN -

Ga-68-SMS

*MDT = Multidisciplinary Tumor Board *CDM = Clincial Decision Making

PET/CT in NET: Diagnostic Algorithm - Restaging Therapy Response

Follow-Up

What is the clinical question to be answered? Status of patient (KPS, ECOG) Repeat p most relevant diagnostic modality

PET/CT, MRI, 4-phase CT

Decision on further therapeutic strategy

Use most relevant diagnostic modality

PET/CT (SMS, FDG, DOPA In addition when needed -Endoscopy -EUS EUS -Ultrasound -Fluoride PET/CT -…

Depending on the clinical question, primarily a whole-body diagnostic approch should be chosen.

Conclusion B Baum ett al. l R Recentt R Res C Cancer R Res. 170 170:225-42 225 42 (2008) Receptor PET/CT using Ga-68-labeled somatostatin analogues enables the molecular imaging of neuroendocrine tumors and their metastases with very high diagnostic sensitivity and specificity (n=4 788 Ga-68 PET/CT studies as of August 30, (n=4,788 30 2010) Advantages of Ga-68 SMS PET/CT: The Bad Berka Experience ¾ Quantitative, reproducible data (SUV) which can be used for selecting patients for PRRT and evaluation of therapy response ¾ Fast protocol (60-90 (60 90 min min.), ) patient friendly friendly, low radiation burden (10-12 (10 12 mSv) ¾ Flexibility, daily use, lower (!) cost than Octreotide scintigraphy ¾ A new gold standard for in vivo SMS receptor imaging Future perspectives: new peptides (e.g. for lung, breast, and prostate cancer), general nuclear medicine applications (e (e.g. g lung perfusion PET/CT for detection of PE, myocardial, bone, kidney, liver imaging, infection and many more).

Ga-68 Labeled Tracers in Clinical Use •

[68Ga-DOTA,Tyr3]octreotide (DOTA-TOC)



[68Ga-DOTA,1-Nal]octreotide (DOTA-NOC)*



[68Ga-DOTA]-TATE* Ga DOTA] TATE*



[68Ga-DOTA]-Lanreotide



[68Ga-DOTA]-Bombesin / AMBA AMBA* and DEMOBESIN DEMOBESIN*



[68Ga-DOTA]-D-Glu-Gastrin*



[68Ga Ga-DOTA]-F(ab’) O ] (ab )2-herceptin e cept



68Ga-Citrate



68Ga-DOTA-Tyrosin* y



68Ga-DOTA-HSA

Microspheres*



68Ga-NOTA-RGD

(angiogenesis)*



68Ga-BPAMP



68Ga-DOTA-



68Ga-DOTA-SHAL



…and many more to come!

(osteoblastic metastases)*

α-MSH (melanoma)* (lymphoma)*

*first use in Bad Berka

FUTURE DIRECTIONS F th generation Fourth ti peptides tid Antagonists of radiolabeled peptides may be superior to agonists Pansomatostatins: P t t ti t targeting ti a broader b d subtype and tumor spectrum M ltireceptor targeting Multireceptor

Loading...

MOLECULAR IMAGING AND PEPTIDE RECEPTOR MOLECULAR

MOLECULAR IMAGING AND PEPTIDE RECEPTOR RADIONUCLIDE THERAPY (PRRNT) OF NEUROENDOCRINE TUMORS: CURRENT STATE AND FUTURE PERSPECTIVES Professor Dr. Rich...

904KB Sizes 2 Downloads 18 Views

Recommend Documents

Molecular adaptation and resilience of the insect's nuclear receptor USP
Oct 5, 2012 - As an illustration, the percentage of codons with a dN/dS above 0.05 is 20% in Mecopterida and only 5% in

molecular cloning and expression study of growth-factor receptor
May 25, 2011 - itu, kajian ini dijalankan untuk menyiasat corak ekspresi Grb7 dalam proses perkembangan ikan zebra, mema

Biochemistry and Molecular Biology
Walker,. John M., 1948– III. Title. QP519.7.P75 2009. 6120.015–dc22 2009043277. ISBN 978-0-521-51635-8 Hardback. ISB

Molecular cloning of a novel scavenger receptor for oxidized low
Nov 1, 2000 - Receptor-mediated endocytosis of oxidized low density lipoprotein (OxLDL)1 by macrophages has been implica

Molecular Dynamics
increasingly important in the life sciences. With faster and more powerful computers larger and more complex systems may

Molecular Symmetry
try operations: NH3, H2O, C6H6, CBrClF. In general, an action which leaves the object looking the same after a transform

Molecular Anthropology
... x-ray equipment prefecture de l'essonne service carte grise adresse kepler 22b namek petition for alien end year bon

Molecular evolution
What is resource management? definition and meaning. Chapter 4 Human Resource Management and the Law - Free download as

Molecular Anthropology
Proteins (/?pro??ti?nz/ or /?pro?ti.?nz/) are large biomolecules, or macromolecules, consisting of one or more long chai

Theranostics Targeting Amino Acid Metabolism for Molecular Imaging
Jul 15, 2016 - such therapies. The amino acid 11C-methionine is a clinically approved agent which is thought to accumula